Mar-02-21 Initiated
Jefferies
Buy
$15
Nov-09-20 Reiterated
H.C. Wainwright
Buy
$19 → $22
Jan-08-20 Initiated
WBB Securities
Speculative Buy
$6
Jan-02-19 Initiated
Canaccord Genuity
Buy
$14
Nov-23-18 Reiterated
H.C. Wainwright
Buy
$55 → $22
Aug-27-18 Initiated
BofA/Merrill
Neutral
$13
Mar-02-18 Downgrade
Raymond James
Strong Buy → Outperform
Oct-24-17 Initiated
Guggenheim
Buy
$44
Jul-18-17 Reiterated
H.C. Wainwright
Buy
$36 → $43
May-19-17 Initiated
Raymond James
Strong Buy
Apr-11-17 Reiterated
H.C. Wainwright
Buy
$33 → $36
Apr-04-17 Reiterated
Wedbush
Outperform
$30 → $34
Apr-04-17 Initiated
Wedbush
Outperform
$30
Oct-27-16 Resumed
Leerink Partners
Outperform
$23
Jun-17-16 Reiterated
H.C. Wainwright
Buy
$31 → $34
May-13-16 Initiated
Robert W. Baird
Outperform
$30
Mar-30-16 Resumed
Cantor Fitzgerald
Buy
$27
Feb-29-16 Initiated
H.C. Wainwright
Buy
$32
Jul-22-15 Initiated
Gabelli & Co
Buy
$34
May-15-15 Initiated
Leerink Partners
Outperform
Apr-12-21 01:59PM
07:12AM
Apr-01-21 04:01PM
Mar-01-21 04:01PM
Feb-25-21 12:01AM
Feb-24-21 04:01PM
02:30PM
Feb-18-21 04:01PM
Feb-17-21 04:01PM
Feb-10-21 12:06AM
Feb-08-21 08:00AM
Feb-01-21 04:05PM
Jan-06-21 08:00AM
Jan-04-21 05:00PM
Dec-25-20 04:07AM
Dec-10-20 09:40PM
Dec-01-20 04:05PM
Nov-12-20 04:01PM
Nov-05-20 06:35PM
04:01PM
02:30PM
Nov-02-20 04:05PM
Oct-29-20 12:35PM
Oct-27-20 08:00AM
Oct-26-20 02:52PM
Oct-21-20 08:00AM
Sep-09-20 04:01PM
09:36AM
Sep-01-20 04:05PM
Aug-25-20 10:17AM
Aug-10-20 08:45AM
08:12AM
07:30AM
Aug-05-20 04:01PM
Aug-03-20 04:05PM
12:31PM
Jul-28-20 04:01PM
12:33PM
Jul-05-20 03:05PM
Jun-12-20 04:46PM Thomson Reuters StreetEvents
May-29-20 08:30AM
May-28-20 08:00AM
May-11-20 04:05PM
07:55AM
07:14AM
06:30AM
Apr-30-20 08:00AM
Apr-28-20 12:14PM
Apr-14-20 12:26PM
Apr-02-20 08:00AM
Apr-01-20 08:00AM
Mar-14-20 10:55AM
Mar-10-20 05:12PM Thomson Reuters StreetEvents
04:01PM
Mar-02-20 04:05PM
Feb-27-20 11:50AM
Feb-26-20 08:00AM
Feb-25-20 05:35PM
04:01PM
Feb-24-20 07:00AM
Feb-17-20 01:36PM
Feb-13-20 04:01PM
Jan-14-20 03:12PM
Dec-20-19 08:38AM
Dec-19-19 09:33PM American City Business Journals +32.20%
08:53AM
07:52AM
Dec-18-19 05:12PM
Dec-13-19 03:06PM
Dec-10-19 12:22PM
Dec-06-19 08:00AM
Dec-02-19 04:05PM
Nov-30-19 11:02AM
Nov-28-19 06:59PM Thomson Reuters StreetEvents
Nov-13-19 12:14PM
Nov-12-19 05:15PM
04:05PM
Nov-05-19 10:31AM
Nov-04-19 04:05PM
Nov-01-19 04:05PM
07:38AM
Oct-31-19 04:05PM
Oct-29-19 10:32AM
Oct-18-19 07:07AM
Oct-17-19 04:05PM
Oct-01-19 04:30PM
10:07AM
Sep-25-19 08:00AM
Sep-24-19 08:50AM
Sep-23-19 01:16PM
Sep-10-19 01:58PM
12:33PM
Sep-09-19 08:00AM
Sep-04-19 08:00AM
Sep-03-19 04:05PM
Aug-30-19 01:31PM
08:00AM
Aug-26-19 04:05PM
Aug-13-19 02:07AM Thomson Reuters StreetEvents
Aug-06-19 05:45PM
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BIGHAM MICHAEL Exec. Chairman of the Board Dec 14 Sale 6.71 26,063 174,883 546,517 Dec 15 07:47 PM Brenner Randall B. Chief Development & Regulatory Dec 14 Sale 6.71 8,760 58,780 128,782 Dec 15 07:50 PM Haskel William M. CLO, General Counsel & Sec. Dec 14 Sale 6.71 6,842 45,910 203,267 Dec 15 07:52 PM Woodrow Adam President & Chief Commercial Dec 14 Sale 6.71 12,855 86,257 271,273 Dec 15 07:54 PM Loh Evan CEO Dec 14 Sale 6.71 26,415 177,245 600,559 Dec 15 07:56 PM Loh Evan CEO Dec 11 Sale 6.95 18,585 129,166 626,974 Dec 15 07:56 PM Woodrow Adam President & Chief Commercial Dec 11 Sale 6.95 9,045 62,863 284,128 Dec 15 07:54 PM Haskel William M. CLO, General Counsel & Sec. Dec 11 Sale 6.95 4,814 33,457 210,109 Dec 15 07:52 PM Brenner Randall B. Chief Development & Regulatory Dec 11 Sale 6.95 6,164 42,840 137,542 Dec 15 07:50 PM BIGHAM MICHAEL Exec. Chairman of the Board Dec 11 Sale 6.95 18,337 127,442 572,580 Dec 15 07:47 PM Loh Evan CEO Nov 13 Sale 5.93 20,928 124,103 645,559 Nov 16 06:36 PM Brenner Randall B. Chief Development & Regulatory Nov 13 Sale 5.93 8,357 49,557 143,706 Nov 16 06:33 PM BIGHAM MICHAEL Exec. Chairman of the Board Nov 13 Sale 5.93 26,250 155,662 590,917 Nov 16 06:30 PM Haskel William M. CLO, General Counsel & Sec. Nov 13 Sale 5.93 6,892 40,870 214,923 Nov 16 06:28 PM Woodrow Adam President & Chief Commercial Nov 13 Sale 5.93 15,000 88,950 293,173 Nov 16 06:23 PM Loh Evan CEO Oct 29 Option Exercise 4.30 39,479 169,760 591,487 Nov 02 04:50 PM Haskel William M. Sr. VP, Sec. & General Counsel May 12 Sale 4.75 4,666 22,164 198,690 May 14 06:42 PM Brenner Randall B. Chief Development & Regulatory May 12 Sale 4.75 6,198 29,440 130,813 May 14 06:38 PM Woodrow Adam President & Chief Commercial May 12 Sale 4.75 4,798 22,790 270,673 May 14 06:30 PM Loh Evan CEO May 12 Sale 4.75 9,595 45,576 552,008 May 14 06:27 PM BIGHAM MICHAEL Exec. Chairman of the Board May 12 Sale 4.68 12,250 57,330 542,167 May 14 06:23 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite